Transmucosal delivery of peptide derivatives

Details for Australian Patent Application No. 2006257792 (hide)

Owner Nastech Pharmaceutical Company Inc.

Inventors Costantino, Henry R.; Li, Ching-Yuan; Kleppe, Mary S.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2006257792

PCT Pub. Number WO2006/135930

Priority 60/748,946 09.12.05 US; 60/689,869 13.06.05 US; 60/690,842 14.06.05 US

Filing date 13 June 2006

Wipo publication date 21 December 2006

International Classifications

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

C07K 7/56 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 14/505 (2006.01) Peptides having more than 20 amino acids

Event Publications

10 January 2008 PCT application entered the National Phase

  PCT publication WO2006/135930 Priority application(s): WO2006/135930

8 January 2009 Alteration of Name

  The name of the applicant has been altered to MDRNA, Inc.

20 May 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006257794-Stable fixed-dose formulations containing a combination of antivirals, method for producing thereof using dry granulation

2006257787-Methods to reduce oxalate concentration by administration of oxalate oxidase crystals